Year: 2021

Paris, 8 November 2021, 7:30 a.m.    PRESS RELEASE Eramet accelerates into the metals for the energy transition and engages the construction of its lithium plant in ArgentinaEramet restarts the construction of its lithium plant in Argentina, leveraging on a strong growth momentum for the demand for this critical metal to the energy transition, which is core in the Group strategic development The construction of the plant, with an annual production of 24,000 tonnes of lithium (LCE1), will start during the first quarter of 2022 with a commissioning scheduled for early 2024 Eramet will control the project, with a 50.1% interest, and will retain operational management responsibility; its partner Tsingshan will finance the plant construction in exchange of a 49.9% interest in the project. Volume produced will be marketed by each shareholder...

Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021 Paris, France, 8 November 2021 – 7:00 a.m. CET– Pixium Vision SA (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that Lloyd Diamond, Chief Executive Officer, and Guillaume Buc, Chief Technology Officer of Pixium Vision, will participate in two master classes at the 3rd Investir Day, being held at the Palais Brongniart in Paris and virtually from November 15 to 23, 2021. Details of the master classes are as follows:Title: Creating a World of Bionic Vision for Those Who Have Lost Their SightA virtual presentation by Lloyd Diamond on Friday, 19 November 2021, 11:30 to 11:50 a.m. CEST – to...

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) — CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone (ACTH). The Company has secured supply of ACTH with one of its strategic partners to meet existing global demand, and will be evaluating the potential of NEURACTHEL® for patients with neurological, endocrinological, and degenerative disorders, who lack alternative therapy. ACTH is from the same family of bioactive hormones – melanocortins – as afamelanotide, the first pharmaceutical product CLINUVEL has successfully commercialised as SCENESSE®.1 Various formulations of ACTH are approved globally for patient use, with 2020 sales...

HONG KONG, Shanghai and FLORHAM PARK, N.J., Nov. 07, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be presented at the upcoming 63rd American Society for Hematology’s (ASH) Annual Meeting and Exposition, taking place on December 11-14, 2021. The meeting will be held virtually and in person at the Georgia World Congress Center in Atlanta, Georgia US. Further details of the presentations are as follows: HMPL-523 Clinical Data PresentationsTitle: Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Patients with Primary Immune Thrombocytopenia: A Randomized, Double-Blind and Placebo-Controlled Phase Ib StudyPresenter: Renchi Yang, MD, Hematology Hospital of the Chinese...

SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the California Governor’s Office of Business and Economic Development (“GO-Biz”). Pursuant to the Agreement, Sorrento has been awarded, subject to the satisfaction of certain milestones specified in the Agreement, an income tax credit from the State of California in an aggregate amount of up to $25,000,000. This incentivized credit is expected to support Sorrento’s vision of growth and expansion within the State of California. “We are grateful to the State of California and GO-Biz for this award,” stated Dr. Henry Ji, Chairman and CEO of...

An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021 Panel members scheduled for discussions at the Iridex booth during AAO meeting on November 13-15th MOUNTAIN VIEW, Calif., Nov. 06, 2021 (GLOBE NEWSWIRE) — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces that an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy and their conclusions for proper dosing and patient selection on November 6 at 10:00am PT/ 1:00pm ET. In the live discussion, attendees will learn recommendations for treatment optimization and settings with the MicroPulse P3® Probe, understand the concept of fluence...

Press release – Paris, le 06/11/2021BOUYGUES GROUP SIGNS PURCHASE AGREEMENT WITH ENGIE TO ACQUIRE EQUANSAcceleration of Bouygues’ development in the strong growth potential multi-technical services sector, at the convergence between the energy, digital and industrial transitions. Creation of a new global leader strongly rooted in France, delivering optimum customer service via a highly complementary geographical and technical match and enhanced innovation capacity. Leveraging the expertise of Equans and of Bouygues’ Energies & Services arm, as well as the close fit between the two businesses, the aim is to make the combined entity the Bouygues group’s largest business segment (by sales and number of employees) and to grow based on a long-term industrial vision. Number of employees: around 96,000; Combined sales: around €16.0...